Insider · CIK 0002004379
Louise Frederika Kooij
Files at NAMS (NewAmsterdam Pharma Co N.V.). First filing Mar 5, 2025, latest Mar 5, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NAMS: NewAmsterdam Pharma Co N.V.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | NAMSsell NewAmsterdam Pharma Co N.V. | $3.1M 150,000 shares | -91% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 26, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Ordinary Shares | +8,269 | $0.00 | $0 | 23,269 | Mar 28, 2025 |
| Mar 26, 2025 | NAMS NewAmsterdam Pharma Co N.V. | AGrant or award Restricted Stock Unitderivative | +8,269 | - | - | 8,269 | Mar 28, 2025 |
| Mar 26, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Restricted Stock Unitderivative | -8,269 | - | - | 0 | Mar 28, 2025 |
| Mar 4, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Ordinary Shares | +150,000 | - | - | 165,000 | Mar 5, 2025 |
| Mar 4, 2025 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Shares | -150,000 | $20.37 | $3.1M | 15,000 | Mar 5, 2025 |
| Mar 4, 2025 | NAMS NewAmsterdam Pharma Co N.V. | MOption exercise Option (right to buy)derivative | -150,000 | $0.00 | $0 | 18,073 | Mar 5, 2025 |
| Jan 7, 2025 | NAMS NewAmsterdam Pharma Co N.V. | AGrant or award Ordinary Shares | +15,000 | - | - | 15,000 | Jan 7, 2025 |
| Jan 2, 2025 | NAMS NewAmsterdam Pharma Co N.V. | AGrant or award Option (right to buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Jan 6, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.